Framingham risk score associates with incident cancer and heart failure
Authors' conclusion
The FRS associates with new-onset cancer or HF, implicating a broader clinical application of the FRS beyond ASCVD risk stratification in cardio-oncology.
Study context
- Population
- PREVEND participants (mean age 49 ± 13 years, 50% female); validation in UK BiobankPREVEND
- Participants
- 8,123 participants
- Comparison
- Highest vs lowest Framingham risk score (FRS) tertile
- Primary endpoint
- Incident cancer or HF
- Follow-up
- Median 17.46 years (cancer), 23.39 years (HF)
Methodological detailsexternal validation
- External validation
Primary result
As reported in the abstract
Subdistribution hazard ratio
2.32
P < 0.001
cancer
Subdistribution hazard ratio
10.08
P < 0.001
Heart failure (HF)
- Incident cancer
- 1176
- Incident HF
- 758
Further findings
| Outcome | sHR | P value |
|---|---|---|
| New-onset cancer and HF (UK Biobank validation, n = 389942)Highest FRS tertile vs Lowest FRS tertile · cancer | 2.05 | P < 0.001 |
| New-onset cancer and HF (UK Biobank validation, n = 389942)Highest FRS tertile vs Lowest FRS tertile · HF | 5.99 | P < 0.001 |
Survival (PREVEND)
- Worst survival in highest FRS tertile
- log-rank P < 0.001
Original publication
Framingham risk score associates with incident cancer and heart failure. Eur J Prev Cardiol. Published 27 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →